Passive transdermal drug delivery systems

The skin has evolved as a formidable barrier against invasion by external microorganisms and against the prevention of water loss. Notwithstanding this, transdermal drug delivery systems have been designed with the aim of providing continuous controlled delivery of drugs via this barrier to the systemic circulation. There are numerous systems now available that effectively deliver drugs across the skin. These include reservoir devices, matrix diffusion-controlled devices, multiple polymer devices, and multilayer matrix systems. This review article focuses on the design characteristics and composition of the main categories of passive transdermal delivery device available.Mechanisms controlling release of the active drug from these systems as well as patch size and irritation problems will be considered. Recent developments in the field are highlighted including advances in patch design as well as the increasing number of drug molecules now amenable to delivery via this route. From the early complex patch designs, devices have now evolved towards simpler, matrix formulations. One of the newer technologies to emerge is the delivery-optimized thermodynamic (DOT) patch system, which allows greater drug loading to be achieved in a much smaller patch size. With the DOT technology, drug is loaded in an acrylic-based adhesive. The drug/acrylic blend is dispersed through silicone adhesive, creating a semi-solid suspension. This overcomes the problem with conventional drug-in-adhesive matrix patches, in which a large drug load in the adhesive reservoir can compromise the adhesive properties or necessitate a large patch size.Transdermal drug delivery remains an attractive and evolving field offering many benefits over alternative routes of drug delivery. Future developments in the field should address problems relating to irritancy and sensitization, which currently exclude a number of therapeutic entities from delivery via this route. It is likely that further innovations in matrix composition and formulation will further expand the number of candidate drugs available for transdermal delivery.

[1]  S. Easthope,et al.  Rotigotine: in Parkinson's disease. , 2005, CNS drugs.

[2]  A. Genazzani,et al.  Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. , 1995, Maturitas.

[3]  Yannic B Schuetz,et al.  Emerging strategies for the transdermal delivery of peptide and protein drugs , 2005, Expert opinion on drug delivery.

[4]  Mark R Prausnitz,et al.  Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.

[5]  K. Higaki,et al.  Strategies for overcoming the stratum corneum , 2003 .

[6]  A. Fisher,et al.  Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. , 2001, JAMA.

[7]  J. Russell Witchcraft in the Middle Ages , 1972 .

[8]  L. Prisant Transdermal Clonidine Skin Reactions , 2002, Journal of clinical hypertension.

[9]  V. Shah,et al.  In vitro dissolution profile of transdermal nitroglycerin patches using paddle method , 1986 .

[10]  M. Roberts,et al.  Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? , 2004, Current drug delivery.

[11]  J Hadgraft,et al.  Passive enhancement strategies in topical and transdermal drug delivery. , 1999, International journal of pharmaceutics.

[12]  T. Higuchi,et al.  Physical Chemical analysis of Percutaneous Absorption Process from Creams and Ointments , 1960 .

[13]  R. Guy,et al.  Transdermal drug delivery : developmental issues and research initiatives , 1989 .

[14]  R. Pfeiffer A promising new technology for Parkinson’s disease , 2005, Neurology.

[15]  D. McTavish,et al.  Transdermal Estradiol , 1992, Drugs & aging.

[16]  Wendy Young,et al.  D-TRANS Technology , 2002 .

[17]  R. Guy,et al.  Rate control in transdermal drug delivery , 1992 .

[18]  B. Finnin,et al.  The transdermal revolution. , 2004, Drug discovery today.

[19]  O. Nagata,et al.  [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. , 2002, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[20]  B. K. Schwartz,et al.  Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch , 1988, Contact dermatitis.

[21]  E. McBurney,et al.  Contact dermatitis to transdermal estradiol system. , 1989, Journal of the American Academy of Dermatology.